Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

Por Ansell, Stephen M., Novak, Anne J., Ziesmer, Steven, Price-Troska, Tammy, LaPlant, Betsy, Dillon, Stacey R., Witzig, Thomas E.
Publicado em 2009

N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy

Por Crozier, Jennifer A., Advani, Pooja P., LaPlant, Betsy, Hobday, Timothy, Jaslowski, Anthony J., Moreno-Aspitia, Alvaro, Perez, Edith A.
Publicado no Clin Breast Cancer (2015)

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

Por Ballman, Karla V., Buckner, Jan C., Brown, Paul D., Giannini, Caterina, Flynn, Patrick J., LaPlant, Betsy R., Jaeckle, Kurt A.
Publicado em 2007

The Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus Results in Clinical Responses and Mobilization of CLL Cells into...

Por Zent, Clive S., LaPlant, Betsy R., Johnston, Patrick B., Call, Timothy G., Habermann, Thomas M., Micallef, Ivana N., Witzig, Thomas E.
Publicado em 2010

Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression

Por Shanafelt, Tait D., Hanson, Curtis, Dewald, Gordon W., Witzig, Thomas E., LaPlant, Betsy, Abrahamzon, Jennifer, Jelinek, Diane F., Kay, Neil E.
Publicado em 2008

Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement

Por Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pavey, Emily S., Nowakowski, Grzegorz S., Zent, Clive S.
Publicado no Leuk Lymphoma (2012)

MBL or CLL: Which Classification Best Categorizes the Clinical Course of Patients with an Absolute Lymphocyte Count ≥5 × 10(9)/L but a B-cell Lymphocyte Count <5 × 10(9)/L?

Por Shanafelt, Tait D., Kay, Neil E., Call, Tim G., Zent, Clive S., Jelinek, Diane F., LaPlant, Betsy, Morice, William G., Hanson, Curtis A.
Publicado em 2008

Brief Report: Pre-treatment Angiogenic Cytokines Predict Response to Chemoimmunotherapy in Patients with CLL

Por Shanafelt, Tait D., Byrd, John C., LaPlant, Betsy, Zent, Clive S., Call, Tim, Secreto, Charla, Grever, Michael R., Lin, Thomas S., Kay, Neil E.
Publicado em 2009

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

Por Cashen, Amanda, Juckett, Mark, Jumonville, Alcee, Litzow, Mark, Flynn, P. J., Eckardt, John, LaPlant, Betsy, Laumann, Kristina, Erlichman, Charles, DiPersio, John
Publicado em 2011

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Por Kumar, Shaji K., LaPlant, Betsy, Chng, Wee Joo, Zonder, Jeffrey, Callander, Natalie, Fonseca, Rafael, Fruth, Briant, Roy, Vivek, Erlichman, Charles, Stewart, A. Keith
Publicado no Blood (2015)

Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab and PGG Beta Glucan is Well Tolerated and Achieves High Complete Remission Rates

Por Zent, Clive S., Call, Timothy G., Bowen, Deborah A., Conte, Michael J., LaPlant, Betsy R., Witzig, Thomas E., Ansell, Stephen M., Weiner, George J.
Publicado no Leuk Lymphoma (2015)

Induced Resistance to Ofatumumab Mediated Cell Clearance Mechanisms, Including Complement Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

Por Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pettinger, Adam M., Shanafelt, Tait D., Nowakowski, Grzegorz S., Zent, Clive S.
Publicado no J Immunol (2014)

Direct and Complement Dependent Cytotoxicity in CLL Cells from Patients with High Risk Early Stage Chronic Lymphocytic Leukemia (CLL) Treated with Alemtuzumab and Rituximab

Por Zent, Clive S., Secreto, Charla R., LaPlant, Betsy R., Bone, Nancy D., Call, Timothy G., Shanafelt, Tait D., Jelinek, Diane F., Tschumper, Renee C., Kay, Neil E.
Publicado em 2008

Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab and Rituximab

Por Zent, Clive S., Call, Timothy G., Shanafelt, Tait D., Tschumper, Renee T., Jelinek, Diane F., Bowen, Deborah A., Secreto, Charla R., LaPlant, Betsy R., Kabat, Brian F., Kay, Neil E.
Publicado em 2008

Pentostatin and Rituximab Therapy for Previously Untreated B-CLL

Por Kay, Neil E., Wu, Wenting, Kabat, Brian, LaPlant, Betsy, Lin, Thomas S., Byrd, John C., Jelinek, Diane F., Grever, Michael R., Zent, Clive S., Call, Timothy G., Shanafelt, Tait D.
Publicado em 2010

The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCT...

Por Johnston, Patrick B., LaPlant, Betsy, McPhail, Ellen, Habermann, Thomas M., Inwards, David J., Micallef, Ivana N., Colgan, Joseph P., Nowakowski, Grzegorz S., Ansell, Stephen M., Witzig, Thomas E.
Publicado no Lancet Haematol (2016)

A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia

Por Kay, Neil E., Strati, Paolo, LaPlant, Betsy R., Leis, Jose F., Nikcevich, Daniel, Call, Timothy G., Pettinger, Adam M., Lesnick, Connie E., Hanson, Curtis A., Shanafelt, Tait D.
Publicado no Oncotarget (2016)

Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL)

Por Shanafelt, Tait, Zent, Clive, Byrd, John, Erlichman, Charles, LaPlant, Betsy, Ghosh, Asish, Call, Timothy, Villalona-Calero, Miguel, Jelinek, Diane, Bowen, Deborah, Laumann, Kristina, Wu, Wenting, Hanson, Curtis, Kay, Neil
Publicado em 2010

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated CLL

Por Shanafelt, Tait, Lanasa, Mark C., Call, Timothy G, Beaven, Anne W., Leis, Jose F., LaPlant, Betsy, Bowen, Deborah, Conte, Michael, Jelinek, Diane F., Hanson, Curtis A., Kay, Neil E., Zent, Clive S.
Publicado em 2013

Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia

Por Nowakowski, Grzegorz S., Hoyer, James D., Shanafelt, Tait D., Zent, Clive S., Call, Timothy G., Bone, Nancy D., LaPlant, Betsy, Dewald, Gordon W., Tschumper, Renee C., Jelinek, Diane F., Witzig, Thomas E., Kay, Neil E.
Publicado em 2009